Compare Tango Therapeutics Inc. (TNGX) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs State Street PDR S&P Retail ETF — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while State Street PDR S&P Retail ETF trades at $84.83 (market cap $374.32M). The key difference: Tango Therapeutics Inc. is far larger — about 10× State Street PDR S&P Retail ETF's market cap, and Tango Therapeutics Inc. is more actively traded (9,619,106 versus 3,523,512). Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and State Street PDR S&P Retail ETF for 45 Days on average.
| TNGX | XRT | |
|---|---|---|
Market Cap | $3.75B | $374.32M |
Volume | 9,619,106 | 3,523,512 |
Sector | Health | Broad Market / Factor |
52-Week High | $32.90 | $92.35 |
52-Week Low | $7.50 | $77.28 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
XRT (SPDR S&P Retail ETF) trades at $84.33, showing minimal daily movement with a 0.21% gain. Technical indicators present a mixed picture with bearish moving averages but neutral overall signals. The ETF faces headwinds from higher interest rates and inflation impacting consumer sentiment, with recent retail sales showing volatility. XRT has underperformed the broader market year-to-date, reflecting sector-specific challenges in the retail landscape.
The retail sector outlook remains cautious amid macroeconomic pressures, though potential trade resolution benefits and holiday sales projections offer some optimism. Key risks include consumer spending sensitivity to economic conditions and competitive pressures. Analyst sentiment leans neutral with expectations of continued relative underperformance versus broader market indices into 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
